查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1984089

功能基因体学市场：依产品类型、技术、应用和最终用户划分－2026-2032年全球市场预测

Functional Genomics Market by Product Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，功能基因体学市场价值将达到 10.8 亿美元，到 2026 年将成长到 12.3 亿美元，到 2032 年将达到 25.7 亿美元，复合年增长率为 13.08%。

主要市场统计数据
基准年 2025 10.8亿美元
预计年份：2026年 12.3亿美元
预测年份 2032 25.7亿美元
复合年增长率 (%) 13.08%

基于收集的信息，对功能基因组学进行战略概述，重点关注技术融合、解释挑战以及研究和临床相关人员。

功能基因组学融合了分子生物学、计算分析和转化研究，将基因组序列数据转化为可操作的生物学见解。仪器、试剂化学和资讯科学的进步，使该领域从假设主导的单基因研究转向高通量系统方法，从而阐明调控网络、突变功能和细胞异质性。这种发展使得研究人员和临床医生能够以前所未有的分辨率揭示基因表现动态、表观遗传修饰和基因型-表型关係。

调查方法、整合解决方案和不断变化的监管预期方面的创新正在重塑功能基因组学的应用路径和经营模式。

功能基因组学领域正经历着一场变革性的转型，其驱动力来自调查方法、数据整合以及新兴的转化应用预期等方面的创新。在调查方法方面，长读长定定序和单细胞技术的成熟拓展了可检测突变和细胞状态的范围，而聚合酵素链锁反应(PCR) 和标靶检测技术的演进则持续提供经济高效的检验途径。伴随这些技术进步，云端原生分析工具和机器学习框架的蓬勃发展也使得可扩展的解读和可重复的工作流程成为可能。

2025 年贸易措施的营运影响，以及相关人员为维持调查和服务交付的连续性而实施的策略供应链调整。

关税的引入和贸易政策的调整可能会在全球生命科学供应链中造成重大摩擦，影响试剂分销、仪器采购和软体许可等各个环节。特别是，美国在2025年实施的措施影响了筹资策略和合约条款，促使製造商和经销商重新评估其供应商网路、库存缓衝和物流紧急时应对计画。这些贸易政策的变化凸显了供应链韧性的重要性，以及为维持科学研究和诊断工作流程的连续性而实现采购管道多元化的必要性。

详细的細項分析揭示了产品、技术、应用和最终用户的交集，从而决定了产品采用的优先顺序和商业化策略。

市场区隔洞察清晰地揭示了价值创造的集中领域以及营运重点与最终用户需求的契合点。产品类型细分检验表明，产品组合包括耗材和试剂、仪器以及软体和服务，其中软体和服务又可进一步细分为服务和软体产品。这种区分凸显了实体耗材与数位化工作流程之间的相互依存关係，也解释了为何许多组织优先考虑整合采购和售后支援。从技术角度来看，产品组合涵盖微阵列平台、次世代定序技术、PCR 和 qPCR 系统、PCR 晶片以及RNA干扰筛检，其中次世代定序本身包含 Illumina、Oxford Nanopore Technologies、Pacific Biosciences 和 Thermo Fisher Ion Torrent 等代表性平台。了解这些技术家族有助于相关人员透过将检测需求与平台优势（例如灵敏度、读取长度和通量）相匹配来优化检测方案。

影响美洲、欧洲、中东和非洲以及亚太地区实施和伙伴关係模式的区域趋势和战略考量

区域趋势对整个功能基因组学生态系统的技术应用、监管路径和伙伴关係模式都具有至关重要的影响。在美洲，研究基础设施、创业投资活动以及大型製药企业和生物技术公司紧密的合作网络正在推动先进平台的早期应用，并促进设备供应商和临床检查室之间的垂直整合合作。该地区的法规结构和报销环境鼓励转化研究计划和公私合作联盟，从而降低临床检验的风险。

竞争格局洞察显示，硬体、试剂和软体的整合策略如何推动功能基因体学领域的差异化和长期客户维繫。

功能基因组学领域的竞争动态由成熟的仪器供应商、专业的试剂创新者和能够实现数据解读和工作流程自动化的软体供应商共同塑造。成熟的仪器供应商持续投资于平台改进和服务网络，重点关注可靠性、处理能力和法规遵从性；而试剂生产商则透过创新的化学技术、批间一致性和简化的样品製备试剂盒来脱颖而出。软体和服务供应商在将原始资料转化为可执行的洞见方面发挥着越来越重要的作用，他们提供整合流程、云端分析和託管服务，从而缩短从实验到决策的时间。

着眼于供应链韧性、互通性分析、服务模式和监管合规性，制定切实可行的策略挑战，以确保竞争优势。

产业领导企业应采取务实的投资组合层面策略，在短期业务永续营运和长期创新之间取得平衡。首先，企业必须优先考虑供应链多元化和合约柔软性，以降低贸易政策波动和零件短缺的风险。这包括选择替代供应商、建立区域采购方案以及在采购合约中加入紧急条款。其次，投资于可互通的软体和标准化资料格式将减少整合摩擦，加速跨平台分析，并使客户能够更有效率地从原始资料得出经过检验的结论。

采用严谨的混合方法研究途径，结合相关人员访谈、文献整合和技术比较评估，确保获得可重复和可操作的见解。

本执行报告的调查方法融合了多种定性和定量方法，以确保研究结果的严谨性和可重复性。主要研究包括与各类相关人员进行结构化访谈和讨论，这些利害关係人包括学术研究人员、临床实验室管理人员、采购经理和产业研发负责人。这些对话有助于深入了解技术需求、应用限制和营运重点，从而为最终的解释性结论奠定基础。

一份统一的报告，明确了实现功能基因组学潜力所需的策略重点、营运驱动因素和基本合作要求。

总而言之，在定序、PCR技术和整合分析技术进步的推动下，功能基因组学正从一门探索性学科转变为发现和临床工作流程中的一项重要组成部分。这项转变要求相关人员协调设备、耗材和软体方面的投资，以实现可重复、高品质资料的生成和解读。供应链韧性、监管合作和人力资源能力是决定哪些机构能够在研究和临床应用情境中扩展功能基因体学的关键因素。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 功能基因体学市场：依产品类型划分

  • 耗材和试剂
  • 装置
  • 软体服务
    • 服务
    • 软体

第九章 功能基因体学市场：依技术划分

  • 微阵列
  • 次世代定序
    • Illumina
    • 牛津奈米孔技术公司
    • 太平洋生物科学
    • Thermo Fisher ION Trent
  • PCR和qPCR
  • PCR晶片
  • RNA干扰筛检

第十章 功能基因体学市场：依应用领域划分

  • 表观遗传学
  • 基因表现分析
  • 基因型鉴定
  • RNA干扰筛检

第十一章 功能基因体学市场：依最终用户划分

  • 学术和研究机构
  • 医院和诊断中心
  • 製药和生物技术公司

第十二章 功能基因体学市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 功能基因体学市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 功能基因体学市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国功能基因体学市场

第十六章：中国功能基因体学市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • 10x Genomics, Inc.
  • Agilent Technologies, Inc.
  • AstraZeneca plc
  • Bio-Rad Laboratories, Inc.
  • Biomatters Limited
  • Bionano Genomics, Inc.
  • C2i Genomics
  • Congenica Ltd.
  • Danaher Corporation
  • Eagle Genomics
  • Eppendorf SE
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche AG
  • Fabric Genomics, Inc.
  • Merck & Co., Inc.
  • Myriad Genetics, Inc.
  • Nest Health Tech Inc.
  • Novogene Co., Ltd.
  • Oxford Nanopore Technologies PLC
  • Pacific Biosciences of California, Inc.
  • Personalis, Inc.
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • Rapid Genomics by LGC Biosearch Technologies
  • Thermo Fisher Scientific Inc.
  • Vizgen, Inc.
Product Code: MRR-2E76C3E47FBB

The Functional Genomics Market was valued at USD 1.08 billion in 2025 and is projected to grow to USD 1.23 billion in 2026, with a CAGR of 13.08%, reaching USD 2.57 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.08 billion
Estimated Year [2026] USD 1.23 billion
Forecast Year [2032] USD 2.57 billion
CAGR (%) 13.08%

An informed strategic overview of functional genomics highlighting technological convergence, interpretive challenges, and operational priorities for research and clinical stakeholders

Functional genomics sits at the intersection of molecular biology, computational analytics, and translational research, translating genomic sequence data into actionable biological understanding. Advances in instrumentation, reagent chemistries, and informatics have moved the discipline from hypothesis-driven single-gene studies to high-throughput systems approaches that reveal regulatory networks, variant function, and cellular heterogeneity. This evolution has enabled researchers and clinicians to probe gene expression dynamics, epigenetic modifications, and genotype-phenotype relationships with unprecedented resolution.

Consequently, stakeholders across academic institutions, diagnostic centers, and industry are integrating functional genomics into workflows that inform target discovery, biomarker development, and therapeutic stratification. The convergence of next-generation sequencing refinements, novel PCR modalities, and scalable software platforms has reduced technical barriers while increasing the depth and granularity of biological insight. Transitioning from data generation to data interpretation remains a central challenge, necessitating investments in computational expertise, standardized protocols, and cross-disciplinary collaboration.

This executive summary synthesizes contemporary drivers, segmentation nuances, regional dynamics, and strategic imperatives shaping the field. It aims to equip leaders with a concise, evidence-based perspective that supports tactical planning, partnership formulation, and resource allocation in an environment where rapid technological iteration and regulatory shifts co-determine competitive positioning and scientific impact.

How methodological innovation, integrated solutions, and evolving regulatory expectations are reshaping adoption pathways and commercial models in functional genomics

The landscape of functional genomics is undergoing transformative shifts driven by methodological innovation, data integration, and new translational expectations. Methodologically, the maturation of long-read sequencing and single-cell approaches is extending the scope of detectable variants and cellular states, while polymerase chain reaction evolutions and targeted assays continue to provide cost-effective validation pathways. These technical advances are paralleled by a surge in cloud-native analytics and machine learning frameworks that enable scalable interpretation and reproducible workflows.

On the operational front, partnerships between instrument manufacturers, reagent suppliers, and software developers are fostering vertically integrated solutions that reduce time to insight and simplify adoption. At the same time, decentralized testing and point-of-care initiatives are prompting platform providers to optimize for portability, speed, and regulatory compliance. Regulatory expectations are shifting toward greater transparency around assay performance and data provenance, prompting vendors and end users to prioritize validated pipelines and robust quality controls.

Finally, commercial models are adjusting to emphasize recurring revenues from consumables and services alongside one-time instrument sales, thereby reshaping investment and customer engagement strategies. Collectively, these shifts are accelerating the translation of functional genomics from experimental discovery to routine clinical and industrial application, while also raising the bar for interoperability, data governance, and cross-sector collaboration.

Operational implications of 2025 trade measures and strategic supply chain adaptations that stakeholders implemented to sustain research continuity and service delivery

The introduction of tariffs and trade policy adjustments can create material friction across the global life sciences supply chain, affecting reagent flows, instrument procurement, and software licensing ecosystems. In particular, measures implemented in 2025 in the United States have influenced sourcing strategies and contractual terms, prompting manufacturers and distributors to reassess supplier networks, inventory buffers, and logistical contingency plans. These trade policy changes have underscored the importance of supply chain resilience and the need to diversify procurement pathways to maintain continuity for research and diagnostic workflows.

Organizations responded by accelerating regional supplier identification and by exploring manufacturing flexibility, including contract manufacturing and localized reagent production. Procurement teams increased emphasis on multi-sourcing clauses and on renegotiating lead times to mitigate exposure to tariff volatility. Additionally, the tariffs highlighted the strategic value of service offerings and digital delivery models that can be decoupled from physical trade constraints, such as cloud-based analytics subscriptions and remote instrument monitoring services.

From a strategic standpoint, the episode reinforced the imperative for integrated risk assessments that account for policy shifts, and for proactive engagement with logistics partners and customs advisors. Entities that invested in scenario planning and in establishing alternate supply corridors reported more stable operations, while those with single-source dependencies experienced longer recovery timelines. The broader lesson is that trade policy is a persistent variable in operational planning and requires continuous monitoring and adaptive contracting to preserve programmatic momentum.

Deep segmentation analysis revealing product, technology, application, and end-user intersections that determine adoption priorities and commercialization strategies

Insight into market segmentation clarifies where value creation is concentrated and where operational priorities align with end-user needs. When examining segmentation by product type, the landscape includes consumables and reagents, instruments, and software and services, with the latter further divided into services and software offerings; this delineation emphasizes the interdependence of physical consumables and digital workflows and signals why many organizations prioritize integrated purchasing and post-sale support. From a technology perspective, the portfolio spans microarray platforms, next-generation sequencing modalities, PCR and qPCR systems, PCR arrays, and RNA interference screening, with next-generation sequencing itself comprising major platform archetypes such as Illumina, Oxford Nanopore Technologies, Pacific Biosciences, and Thermo Fisher Ion Torrent; understanding these technology families helps stakeholders match assay requirements to platform strengths for sensitivity, read length, and throughput.

Application segmentation highlights core use cases including epigenetics, gene expression analysis, genotyping, and RNA interference screening, each of which imposes distinct requirements on sample preparation, detection sensitivity, and bioinformatics interpretation. Finally, end user segmentation identifies primary demand drivers across academic and research institutes, hospitals and diagnostic centers, and pharmaceutical and biotech companies, illuminating how purchasing rationales differ between discovery-oriented research and regulated clinical environments. By integrating these segmentation lenses, organizations can better prioritize product development, align commercial messaging to user workflows, and design service bundles that reduce adoption friction while improving scientific outcomes.

Comparative regional dynamics and strategic considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape adoption and partnership models

Regional dynamics exert a decisive influence on technology adoption, regulatory pathways, and partnership models across the functional genomics ecosystem. In the Americas, research infrastructure, venture capital activity, and a dense network of large pharmaceutical and biotech organizations drive early adoption of advanced platforms and foster vertically integrated collaborations between instrument vendors and clinical laboratories. Regulatory frameworks and reimbursement environments in this region incentivize translational projects and public-private consortia that de-risk clinical validation pathways.

Across Europe, Middle East & Africa, the landscape is heterogeneous, with pockets of leading academic centers and national initiatives promoting genomics medicine alongside markets where access and infrastructure vary considerably. Harmonization efforts and pan-regional partnerships are pivotal in scaling multi-center studies and in implementing standardized data governance protocols. Meanwhile, capacity building and public health genomics programs are expanding the relevance of decentralized and cost-effective solutions.

In the Asia-Pacific region, rapid investments in genomics infrastructure, a growing diagnostics market, and an expanding base of contract research organizations support accelerated uptake of both established and emerging technologies. Local manufacturing and supportive industrial policies have encouraged supply-chain localization and public-private collaborations, shaping acquisition strategies for instruments, reagents, and informatics platforms. Across all regions, strategic entrants are tailoring their value propositions to reflect local regulatory expectations, reimbursement realities, and ecosystem maturity.

Competitive landscape insights showing how integrated hardware, reagent, and software strategies drive differentiation and long-term customer retention in functional genomics

Competitive dynamics in functional genomics are shaped by a mixture of legacy instrument incumbents, specialized reagent innovators, and software providers enabling data interpretation and workflow automation. Established instrument vendors continue to invest in platform improvements and service networks that emphasize reliability, throughput, and regulatory support, while reagent manufacturers differentiate through novel chemistries, lot-to-lot consistency, and streamlined sample preparation kits. Software and services providers are increasingly essential in converting raw data into usable insights, offering integrated pipelines, cloud analytics, and managed services that reduce the time from experiment to decision.

Strategic activities include collaborations between instrument manufacturers and bioinformatics firms, acquisitions aimed at expanding end-to-end offerings, and partnerships with contract research organizations to embed platforms into large-scale studies. Companies that succeed tend to pair strong technical performance with robust customer support, transparent validation datasets, and flexible commercial models that accommodate both research and clinical buyers. Additionally, investment in education, technical training, and community engagement-such as user forums and application-focused workshops-strengthens market position by lowering adoption barriers and fostering user loyalty.

Going forward, competitive advantage will accrue to organizations that can seamlessly integrate hardware, chemistry, and software, while also demonstrating compliance with evolving regulatory expectations and delivering reproducible results across diverse sample types and study designs.

Actionable strategic imperatives emphasizing supply chain resilience, interoperable analytics, service models, and regulatory readiness to secure competitive advantage

Industry leaders should adopt a pragmatic, portfolio-level approach that balances near-term operational resilience with long-term innovation. First, organizations must prioritize supply chain diversification and contract flexibility to mitigate risks associated with trade policy shifts and component shortages. This includes qualifying alternative suppliers, establishing regional sourcing options, and embedding contingency terms in procurement contracts. Second, investment in interoperable software and standardized data formats will reduce integration friction and accelerate cross-platform analytics, enabling customers to move from raw data to validated conclusions more efficiently.

Third, companies should pivot to service-centric models where appropriate, bundling assays, validation services, and analytics support to create recurring revenue streams and deepen client relationships. Fourth, enhanced regulatory readiness-through preemptive validation studies, rigorous documentation, and proactive engagement with regulators-will shorten clinical adoption pathways and build trust among diagnostic customers. Fifth, leaders must commit to workforce development by supporting end-user training, certification programs, and knowledge transfer initiatives that lower technical barriers and scale adoption.

Finally, strategic partnerships that combine localized manufacturing, regional distribution expertise, and domain-specific bioinformatics capabilities will offer competitive advantages in markets with distinct regulatory and infrastructural profiles. Collectively, these actions will position organizations to convert technological advances into sustained scientific and commercial impact.

Rigorous mixed-method research approach combining stakeholder interviews, literature synthesis, and comparative technology assessment to ensure reproducible, actionable insights

The research methodology underpinning this executive synthesis integrates multiple qualitative and quantitative approaches to ensure rigorous, reproducible insights. Primary research included structured interviews and consultative discussions with a cross-section of stakeholders spanning academic investigators, clinical laboratory directors, procurement leads, and industry R&D heads. These interactions provided contextual understanding of technology needs, adoption inhibitors, and operational priorities that inform interpretive conclusions.

Secondary research comprised review of peer-reviewed literature, conference proceedings, regulatory guidance documents, and company technical disclosures to validate technological trends and to map product portfolios. Where appropriate, comparative technology assessments were conducted to articulate platform strengths and limitations across typical applications such as gene expression profiling, epigenetic analysis, and variant functionalization. Triangulation of primary insights with secondary sources ensured robustness and helped identify consensus themes and areas of friction.

Analytical methods emphasized thematic synthesis over raw extrapolation, with attention to reproducibility, data provenance, and methodological transparency. Limitations of the analysis are acknowledged and are addressed through recommended follow-up assessments and potential commissioning of bespoke studies tailored to specific organizational questions.

Concluding synthesis that distills strategic priorities, operational enablers, and collaborative imperatives required to realize the promise of functional genomics

In summary, functional genomics is transitioning from an exploratory discipline to an operationalized component of discovery and clinical workflows, catalyzed by advances in sequencing, PCR technologies, and integrative analytics. This transition requires stakeholders to align investments across instrumentation, consumables, and software to enable reproducible, high-quality data generation and interpretation. Supply chain resilience, regulatory engagement, and workforce capability are central enablers that will determine which organizations can scale functional genomics across research and clinical use cases.

Strategic focus should concentrate on delivering integrated solutions that reduce total cost of ownership and on cultivating partnerships that bridge academic, clinical, and commercial spheres. Moreover, firms that prioritize interoperability, transparent validation, and end-user training will lower adoption barriers and accelerate the translation of genomic insights into tangible outcomes. The field presents meaningful opportunities for those who can marry technical excellence with pragmatic commercialization and service delivery, while remaining responsive to policy developments and regional market nuances.

Ultimately, success will depend on the capacity to convert complex data into decision-ready evidence, to manage operational risk, and to sustain collaborative ecosystems that amplify scientific discovery and patient impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Functional Genomics Market, by Product Type

  • 8.1. Consumables & Reagents
  • 8.2. Instruments
  • 8.3. Software & Services
    • 8.3.1. Services
    • 8.3.2. Software

9. Functional Genomics Market, by Technology

  • 9.1. Microarray
  • 9.2. Next-Generation Sequencing
    • 9.2.1. Illumina
    • 9.2.2. Oxford Nanopore Technologies
    • 9.2.3. Pacific Biosciences
    • 9.2.4. Thermo Fisher Ion Torrent
  • 9.3. PCR & qPCR
  • 9.4. PCR Arrays
  • 9.5. RNA Interference Screening

10. Functional Genomics Market, by Application

  • 10.1. Epigenetics
  • 10.2. Gene Expression Analysis
  • 10.3. Genotyping
  • 10.4. RNA Interference Screening

11. Functional Genomics Market, by End User

  • 11.1. Academic & Research Institutes
  • 11.2. Hospitals & Diagnostic Centers
  • 11.3. Pharmaceutical & Biotech Companies

12. Functional Genomics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Functional Genomics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Functional Genomics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Functional Genomics Market

16. China Functional Genomics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. 10x Genomics, Inc.
  • 17.6. Agilent Technologies, Inc.
  • 17.7. AstraZeneca plc
  • 17.8. Bio-Rad Laboratories, Inc.
  • 17.9. Biomatters Limited
  • 17.10. Bionano Genomics, Inc.
  • 17.11. C2i Genomics
  • 17.12. Congenica Ltd.
  • 17.13. Danaher Corporation
  • 17.14. Eagle Genomics
  • 17.15. Eppendorf SE
  • 17.16. Eurofins Scientific SE
  • 17.17. F. Hoffmann-La Roche AG
  • 17.18. Fabric Genomics, Inc.
  • 17.19. Merck & Co., Inc.
  • 17.20. Myriad Genetics, Inc.
  • 17.21. Nest Health Tech Inc.
  • 17.22. Novogene Co., Ltd.
  • 17.23. Oxford Nanopore Technologies PLC
  • 17.24. Pacific Biosciences of California, Inc.
  • 17.25. Personalis, Inc.
  • 17.26. QIAGEN N.V.
  • 17.27. Quest Diagnostics Incorporated
  • 17.28. Rapid Genomics by LGC Biosearch Technologies
  • 17.29. Thermo Fisher Scientific Inc.
  • 17.30. Vizgen, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL FUNCTIONAL GENOMICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL FUNCTIONAL GENOMICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES FUNCTIONAL GENOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA FUNCTIONAL GENOMICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY ILLUMINA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY ILLUMINA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY ILLUMINA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY OXFORD NANOPORE TECHNOLOGIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY OXFORD NANOPORE TECHNOLOGIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY OXFORD NANOPORE TECHNOLOGIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY PACIFIC BIOSCIENCES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY PACIFIC BIOSCIENCES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY PACIFIC BIOSCIENCES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY THERMO FISHER ION TORRENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY THERMO FISHER ION TORRENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY THERMO FISHER ION TORRENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY PCR & QPCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY PCR & QPCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY PCR & QPCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY PCR ARRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY PCR ARRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY PCR ARRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY RNA INTERFERENCE SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY RNA INTERFERENCE SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY RNA INTERFERENCE SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY EPIGENETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY EPIGENETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY EPIGENETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY GENE EXPRESSION ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY GENE EXPRESSION ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY GENE EXPRESSION ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY GENOTYPING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY GENOTYPING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY GENOTYPING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY RNA INTERFERENCE SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY RNA INTERFERENCE SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY RNA INTERFERENCE SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS FUNCTIONAL GENOMICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS FUNCTIONAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS FUNCTIONAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS FUNCTIONAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS FUNCTIONAL GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS FUNCTIONAL GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA FUNCTIONAL GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA FUNCTIONAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA FUNCTIONAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA FUNCTIONAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA FUNCTIONAL GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA FUNCTIONAL GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA FUNCTIONAL GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA FUNCTIONAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA FUNCTIONAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA FUNCTIONAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA FUNCTIONAL GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA FUNCTIONAL GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA FUNCTIONAL GENOMICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA FUNCTIONAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA FUNCTIONAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA FUNCTIONAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA FUNCTIONAL GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA FUNCTIONAL GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE FUNCTIONAL GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE FUNCTIONAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE FUNCTIONAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE FUNCTIONAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE FUNCTIONAL GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE FUNCTIONAL GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST FUNCTIONAL GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST FUNCTIONAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST FUNCTIONAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST FUNCTIONAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST FUNCTIONAL GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST FUNCTIONAL GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA FUNCTIONAL GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA FUNCTIONAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA FUNCTIONAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA FUNCTIONAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA FUNCTIONAL GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA FUNCTIONAL GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC FUNCTIONAL GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC FUNCTIONAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC FUNCTIONAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC FUNCTIONAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC FUNCTIONAL GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC FUNCTIONAL GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN FUNCTIONAL GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN FUNCTIONAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN FUNCTIONAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN FUNCTIONAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN FUNCTIONAL GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN FUNCTIONAL GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. GCC FUNCTIONAL GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GCC FUNCTIONAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. GCC FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 139. GCC FUNCTIONAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. GCC FUNCTIONAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 141. GCC FUNCTIONAL GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. GCC FUNCTIONAL GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION FUNCTIONAL GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION FUNCTIONAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION FUNCTIONAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION FUNCTIONAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION FUNCTIONAL GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION FUNCTIONAL GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS FUNCTIONAL GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS FUNCTIONAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS FUNCTIONAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS FUNCTIONAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS FUNCTIONAL GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS FUNCTIONAL GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. G7 FUNCTIONAL GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. G7 FUNCTIONAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. G7 FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 160. G7 FUNCTIONAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. G7 FUNCTIONAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 162. G7 FUNCTIONAL GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 163. G7 FUNCTIONAL GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. NATO FUNCTIONAL GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. NATO FUNCTIONAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. NATO FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 167. NATO FUNCTIONAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. NATO FUNCTIONAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 169. NATO FUNCTIONAL GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. NATO FUNCTIONAL GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES FUNCTIONAL GENOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES FUNCTIONAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES FUNCTIONAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES FUNCTIONAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES FUNCTIONAL GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES FUNCTIONAL GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA FUNCTIONAL GENOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 180. CHINA FUNCTIONAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. CHINA FUNCTIONAL GENOMICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA FUNCTIONAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA FUNCTIONAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA FUNCTIONAL GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA FUNCTIONAL GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)